Regeneron, Parabilis Ink Up-to-$2.3B Antibody-Peptide Conjugate Collaboration

Regeneron, Parabilis Ink Up-to-$2.3B Antibody-Peptide Conjugate Collaboration

Regeneron Pharmaceuticals will partner with Parabilis Medicines to discover and develop an initial five candidates encompassing a new form of antibody-drug conjugates aimed at challenging and historically undruggable targets, through a strategic research collaboration that could generate up to $2.3 billion-plus for the Cambridge, MA, biotech. Regeneron will marry its antibody capabilities with Parabilis’ stabilized helical peptide or Helicon pla…

Regeneron signs $2.32bn deal with Parabilis for Helicon conjugates

Regeneron Pharmaceuticals has signed a $2.32bn deal with Parabilis Medicines to develop therapeutic candidates, with a focus on AHCs.The post Regeneron signs $2.32bn deal with Parabilis for Helicon conjugates appeared first on Hospital Management.